Search alternatives:
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
non decrease » point decrease (Expand Search), note decreased (Expand Search), fold decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a step » _ step (Expand Search)
Showing 19,681 - 19,700 results of 103,177 for search '(( a step decrease ) OR ( 5 ((non decrease) OR (((nn decrease) OR (a decrease)))) ))', query time: 1.52s Refine Results
  1. 19681
    Primary and exploratory statistical analysis: comparison of binding antibody multiplex assay (BAMA) IgG breadth scores at RV144 week 26 and RV305 week 2 (primary analysis) and RV144 week 26 and RV305 week 26 (exploratory analysis).

    Primary and exploratory statistical analysis: comparison of binding antibody multiplex assay (BAMA) IgG breadth scores at RV144 week 26 and RV305 week 2 (primary analysis) and RV14... by LaTonya D. Williams (3140490)

    Published 2023
    Save to List
    Saved in:
  2. 19682
    Primary and exploratory statistical analysis: comparison of binding antibody multiplex assay (BAMA) total IgG and IgG1 response magnitudes at RV144 week 26 versus RV305 week 2, RV305 week 2 versus RV305 week 26, and RV144 week 26 versus RV305 week 26.

    Primary and exploratory statistical analysis: comparison of binding antibody multiplex assay (BAMA) total IgG and IgG1 response magnitudes at RV144 week 26 versus RV305 week 2, RV3... by LaTonya D. Williams (3140490)

    Published 2023
    Save to List
    Saved in:
  3. 19683
    Durability of IgG3 responses.

    Durability of IgG3 responses. by LaTonya D. Williams (3140490)

    Published 2023
    Save to List
    Saved in:
  4. 19684
    Primary statistical analysis: comparison of binding antibody multiplex assay (BAMA) IgG3 response magnitudes between the Combination (ALVAC-HIV + AIDSVAX B/E) group (group 1) and AIDSVAX B/E only group (group 2) at RV305 week 2 and RV305 week 26.

    Primary statistical analysis: comparison of binding antibody multiplex assay (BAMA) IgG3 response magnitudes between the Combination (ALVAC-HIV + AIDSVAX B/E) group (group 1) and A... by LaTonya D. Williams (3140490)

    Published 2023
    Save to List
    Saved in:
  5. 19685
    Primary statistical analysis: comparison of binding antibody multiplex assay (BAMA) IgG4 response magnitudes between the Combination (ALVAC-HIV + AIDSVAX B/E) group (group 1) and AIDSVAX B/E only group (group 2) at RV305 week 2 and RV305 week 26.

    Primary statistical analysis: comparison of binding antibody multiplex assay (BAMA) IgG4 response magnitudes between the Combination (ALVAC-HIV + AIDSVAX B/E) group (group 1) and A... by LaTonya D. Williams (3140490)

    Published 2023
    Save to List
    Saved in:
  6. 19686
    Primary statistical analysis: comparison of binding antibody multiplex assay (BAMA) total IgG and IgG1 response magnitudes between the Combination (ALVAC-HIV + AIDSVAX B/E) group (group 1) and AIDSVAX B/E only group (group 2) at RV305 week 2 and RV305 week 26.

    Primary statistical analysis: comparison of binding antibody multiplex assay (BAMA) total IgG and IgG1 response magnitudes between the Combination (ALVAC-HIV + AIDSVAX B/E) group (... by LaTonya D. Williams (3140490)

    Published 2023
    Save to List
    Saved in:
  7. 19687
    Primary and exploratory statistical analysis: comparison of binding antibody multiplex assay (BAMA) IgG3 breadth scores at RV144 week 26 versus RV305 week 2 (primary analysis), RV305 week 2 versus RV305 week 26, and RV144 week 26 versus RV305 week 26 (exploratory analysis).

    Primary and exploratory statistical analysis: comparison of binding antibody multiplex assay (BAMA) IgG3 breadth scores at RV144 week 26 versus RV305 week 2 (primary analysis), RV3... by LaTonya D. Williams (3140490)

    Published 2023
    Save to List
    Saved in:
  8. 19688
    Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58

    Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58 by Avivit Cahn (10072991)

    Published 2022
    Save to List
    Saved in:
  9. 19689
    Durability of Env gp120 IgG responses.

    Durability of Env gp120 IgG responses. by LaTonya D. Williams (3140490)

    Published 2023
    Save to List
    Saved in:
  10. 19690
    Cyclization Decoded: Engineering Amylomaltase for Efficient α‑Glucan Transformations

    Cyclization Decoded: Engineering Amylomaltase for Efficient α‑Glucan Transformations by Han Liu (288039)

    Published 2025
    “…Here, we harness large-scale computations in synergy with biochemical experiments to unravel, at atomic resolution, the full covalent and noncovalent catalytic mechanism of AMs, revealing that cyclization (12.8 kcal/mol) outcompetes hydrolysis (17.5 kcal/mol) as the dominant pathway. Furthermore, we identify that postglycosylation noncovalent polysaccharide chain transfer emerges as the decisive factor in cyclization, particularly for AM–degree of polymerization (DP) greater than 30 substrate complexes, where this noncovalent step (≥13.6 kcal/mol) dictates the rate of CA production. 57 variants with enhanced activity (up to a 2.3-fold increase) were engineered in our biochemical experiments by strategically modulating the chain transfer step. …”
    Save to List
    Saved in:
  11. 19691
    Image_6_A Novel Therapeutic Mechanism of Imipridones ONC201/ONC206 in MYCN-Amplified Neuroblastoma Cells via Differential Expression of Tumorigenic Proteins.TIF

    Image_6_A Novel Therapeutic Mechanism of Imipridones ONC201/ONC206 in MYCN-Amplified Neuroblastoma Cells via Differential Expression of Tumorigenic Proteins.TIF by Sarra El-Soussi (11228799)

    Published 2021
    “…The protein expression of tumorigenic NMYC, Sox-2, Oct-4, FABP5, and HMGA1 significantly decreased 48 h post-drug treatment, whereas cleaved PARP1/caspase-3 and γH2AX increased 72 h post-drug treatment, compared with vehicle-treated cells in the MYCN-amplified IMR-32 cell line. …”
    Save to List
    Saved in:
  12. 19692
    Image_1_A Novel Therapeutic Mechanism of Imipridones ONC201/ONC206 in MYCN-Amplified Neuroblastoma Cells via Differential Expression of Tumorigenic Proteins.TIF

    Image_1_A Novel Therapeutic Mechanism of Imipridones ONC201/ONC206 in MYCN-Amplified Neuroblastoma Cells via Differential Expression of Tumorigenic Proteins.TIF by Sarra El-Soussi (11228799)

    Published 2021
    “…The protein expression of tumorigenic NMYC, Sox-2, Oct-4, FABP5, and HMGA1 significantly decreased 48 h post-drug treatment, whereas cleaved PARP1/caspase-3 and γH2AX increased 72 h post-drug treatment, compared with vehicle-treated cells in the MYCN-amplified IMR-32 cell line. …”
    Save to List
    Saved in:
  13. 19693
    Image_7_A Novel Therapeutic Mechanism of Imipridones ONC201/ONC206 in MYCN-Amplified Neuroblastoma Cells via Differential Expression of Tumorigenic Proteins.TIF

    Image_7_A Novel Therapeutic Mechanism of Imipridones ONC201/ONC206 in MYCN-Amplified Neuroblastoma Cells via Differential Expression of Tumorigenic Proteins.TIF by Sarra El-Soussi (11228799)

    Published 2021
    “…The protein expression of tumorigenic NMYC, Sox-2, Oct-4, FABP5, and HMGA1 significantly decreased 48 h post-drug treatment, whereas cleaved PARP1/caspase-3 and γH2AX increased 72 h post-drug treatment, compared with vehicle-treated cells in the MYCN-amplified IMR-32 cell line. …”
    Save to List
    Saved in:
  14. 19694
    Image_4_A Novel Therapeutic Mechanism of Imipridones ONC201/ONC206 in MYCN-Amplified Neuroblastoma Cells via Differential Expression of Tumorigenic Proteins.TIF

    Image_4_A Novel Therapeutic Mechanism of Imipridones ONC201/ONC206 in MYCN-Amplified Neuroblastoma Cells via Differential Expression of Tumorigenic Proteins.TIF by Sarra El-Soussi (11228799)

    Published 2021
    “…The protein expression of tumorigenic NMYC, Sox-2, Oct-4, FABP5, and HMGA1 significantly decreased 48 h post-drug treatment, whereas cleaved PARP1/caspase-3 and γH2AX increased 72 h post-drug treatment, compared with vehicle-treated cells in the MYCN-amplified IMR-32 cell line. …”
    Save to List
    Saved in:
  15. 19695
    Image_8_A Novel Therapeutic Mechanism of Imipridones ONC201/ONC206 in MYCN-Amplified Neuroblastoma Cells via Differential Expression of Tumorigenic Proteins.TIF

    Image_8_A Novel Therapeutic Mechanism of Imipridones ONC201/ONC206 in MYCN-Amplified Neuroblastoma Cells via Differential Expression of Tumorigenic Proteins.TIF by Sarra El-Soussi (11228799)

    Published 2021
    “…The protein expression of tumorigenic NMYC, Sox-2, Oct-4, FABP5, and HMGA1 significantly decreased 48 h post-drug treatment, whereas cleaved PARP1/caspase-3 and γH2AX increased 72 h post-drug treatment, compared with vehicle-treated cells in the MYCN-amplified IMR-32 cell line. …”
    Save to List
    Saved in:
  16. 19696
    Image_9_A Novel Therapeutic Mechanism of Imipridones ONC201/ONC206 in MYCN-Amplified Neuroblastoma Cells via Differential Expression of Tumorigenic Proteins.TIF

    Image_9_A Novel Therapeutic Mechanism of Imipridones ONC201/ONC206 in MYCN-Amplified Neuroblastoma Cells via Differential Expression of Tumorigenic Proteins.TIF by Sarra El-Soussi (11228799)

    Published 2021
    “…The protein expression of tumorigenic NMYC, Sox-2, Oct-4, FABP5, and HMGA1 significantly decreased 48 h post-drug treatment, whereas cleaved PARP1/caspase-3 and γH2AX increased 72 h post-drug treatment, compared with vehicle-treated cells in the MYCN-amplified IMR-32 cell line. …”
    Save to List
    Saved in:
  17. 19697
    Image_2_A Novel Therapeutic Mechanism of Imipridones ONC201/ONC206 in MYCN-Amplified Neuroblastoma Cells via Differential Expression of Tumorigenic Proteins.TIF

    Image_2_A Novel Therapeutic Mechanism of Imipridones ONC201/ONC206 in MYCN-Amplified Neuroblastoma Cells via Differential Expression of Tumorigenic Proteins.TIF by Sarra El-Soussi (11228799)

    Published 2021
    “…The protein expression of tumorigenic NMYC, Sox-2, Oct-4, FABP5, and HMGA1 significantly decreased 48 h post-drug treatment, whereas cleaved PARP1/caspase-3 and γH2AX increased 72 h post-drug treatment, compared with vehicle-treated cells in the MYCN-amplified IMR-32 cell line. …”
    Save to List
    Saved in:
  18. 19698
    Image_3_A Novel Therapeutic Mechanism of Imipridones ONC201/ONC206 in MYCN-Amplified Neuroblastoma Cells via Differential Expression of Tumorigenic Proteins.TIF

    Image_3_A Novel Therapeutic Mechanism of Imipridones ONC201/ONC206 in MYCN-Amplified Neuroblastoma Cells via Differential Expression of Tumorigenic Proteins.TIF by Sarra El-Soussi (11228799)

    Published 2021
    “…The protein expression of tumorigenic NMYC, Sox-2, Oct-4, FABP5, and HMGA1 significantly decreased 48 h post-drug treatment, whereas cleaved PARP1/caspase-3 and γH2AX increased 72 h post-drug treatment, compared with vehicle-treated cells in the MYCN-amplified IMR-32 cell line. …”
    Save to List
    Saved in:
  19. 19699
    The probability of detection (POD) of the sign of change in the CMIP5 climate model simulations from the period 1951–1977 to the period 1978–2004 for the four combinations of warm/wet, warm/dry, cold/wet, and cold/dry extremes with respect to CRU observations

    The probability of detection (POD) of the sign of change in the CMIP5 climate model simulations from the period 1951–1977 to the period 1978–2004 for the four combinations of warm/... by Zengchao Hao (557031)

    Published 2013
    “…The POD is defined as the fraction of grids in which the sign of change in the number of joint occurrences (increase, decrease, neutral) in CMIP5 model simulations agrees with the ground-based observations.…”
    Save to List
    Saved in:
  20. 19700
    Anti-tumor effects of different paclitaxel formulations after intravenous administration to H22 tumor-bearing mice.

    Anti-tumor effects of different paclitaxel formulations after intravenous administration to H22 tumor-bearing mice. by Yue Gao (263086)

    Published 2021
    Save to List
    Saved in:

Search Tools: